AI technology is creating a recalibration of the finance function and this is opening up exciting possibilities along with ...
Advancement of next-generation APJ agonists with discontinuation of azelaprag BioAge has terminated development of azelaprag, an orally available small molecule agonist of APJ, for obesity and other ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback